Japan
· Delayed Price · Currency is JPY Rohto Pharmaceutical Co.,Ltd. Statistics
Total Valuation
Rohto Pharmaceutical Co.,Ltd. has a market cap or net worth of JPY 813.09 billion. The enterprise value is 784.80 billion.
| Market Cap | 813.09B |
| Enterprise Value | 784.80B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | Sep 27, 2024 |
Share Statistics
Rohto Pharmaceutical Co.,Ltd. has 228.14 million shares outstanding. The number of shares has decreased by -0.01% in one year.
| Shares Outstanding | 228.14M |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 3.56% |
| Owned by Institutions (%) | 43.25% |
| Float | 189.45M |
Valuation Ratios
The trailing PE ratio is 26.89 and the forward PE ratio is 23.16. Rohto Pharmaceutical Co.,Ltd.'s PEG ratio is 2.07.
| PE Ratio | 26.89 |
| Forward PE | 23.16 |
| PS Ratio | 2.92 |
| PB Ratio | 3.15 |
| P/FCF Ratio | n/a |
| PEG Ratio | 2.07 |
Enterprise Valuation
| EV / Earnings | 25.88 |
| EV / Sales | 2.82 |
| EV / EBITDA | 16.13 |
| EV / EBIT | 19.75 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.77 |
| Quick Ratio | 1.18 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 0.93 |
| Debt / FCF | n/a |
| Interest Coverage | 187.25 |
Financial Efficiency
Return on equity (ROE) is 12.67% and return on invested capital (ROIC) is 9.32%.
| Return on Equity (ROE) | 12.67% |
| Return on Assets (ROA) | 6.92% |
| Return on Capital (ROIC) | 9.32% |
| Revenue Per Employee | 38.30M |
| Profits Per Employee | 4.18M |
| Employee Count | 7,259 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 2.21 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.67% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -4.67% |
| 50-Day Moving Average | 3,441.78 |
| 200-Day Moving Average | 3,148.27 |
| Relative Strength Index (RSI) | 52.19 |
| Average Volume (20 Days) | 565,300 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Rohto Pharmaceutical Co.,Ltd. had revenue of JPY 278.03 billion and earned 30.33 billion in profits. Earnings per share was 132.56.
| Revenue | 278.03B |
| Gross Profit | 160.59B |
| Operating Income | 40.26B |
| Pretax Income | 41.37B |
| Net Income | 30.33B |
| EBITDA | 49.17B |
| EBIT | 40.26B |
| Earnings Per Share (EPS) | 132.56 |
Balance Sheet
The company has 73.62 billion in cash and 45.87 billion in debt, giving a net cash position of 27.75 billion or 121.65 per share.
| Cash & Cash Equivalents | 73.62B |
| Total Debt | 45.87B |
| Net Cash | 27.75B |
| Net Cash Per Share | 121.65 |
| Equity (Book Value) | 257.25B |
| Book Value Per Share | 1,129.94 |
| Working Capital | 92.15B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 57.76%, with operating and profit margins of 14.48% and 10.91%.
| Gross Margin | 57.76% |
| Operating Margin | 14.48% |
| Pretax Margin | 14.88% |
| Profit Margin | 10.91% |
| EBITDA Margin | 17.68% |
| EBIT Margin | 14.48% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 33.00, which amounts to a dividend yield of 0.93%.
| Dividend Per Share | 33.00 |
| Dividend Yield | 0.93% |
| Dividend Growth (YoY) | 29.17% |
| Years of Dividend Growth | 3 |
| Payout Ratio | n/a |
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.93% |
| Earnings Yield | 3.72% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on December 29, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Dec 29, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Rohto Pharmaceutical Co.,Ltd. has an Altman Z-Score of 4.9.
| Altman Z-Score | 4.9 |
| Piotroski F-Score | n/a |